The year’s biggest deal is far from certain (AET, CVS)
|12/05/2017||Posted by BusinessMediaguide.Com under General World News||
- CVS Health’s massive acquisition of Aetna could face heightened regulatory scrutiny amid the Trump administration’s new regulatory regime.
- Aetna’s stock is trading about 10% below the per-share offer price, reflecting investor uncertainty that the deal will get approval.
A year ago, CVS Health‘s $69 billion acquisition of Aetna would’ve probably skated past regulatory proceedings. But things have changed under the Trump administration, and investors don’t look particularly confident that the mega-deal will be approved.
This uncertainty around the deal — the biggest to be announced in 2017 — is being reflected by Aetna’s stock, read more >>>